Huntington’s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
After the successful cloning of the first gene for a polyglutamine disease in 1991, the expanded polyglutamine tract in the nine polyglutamine disease proteins became an obvious therapeutic target. Early hypotheses were that misfolded, precipitated protein could be a universal pathogenic mechanism. However, new data are accumulating on Huntington’s disease and other polyglutamine diseases that appear to contradict the toxic aggregate hypothesis. Recent data suggest that the toxic species of protein in these diseases may be soluble mutant conformers, and that the protein context of expanded polyglutamine is critical to understanding disease specificity. Here we discuss recent publications that define other important therapeutic targets for polyglutamine‐mediated neurodegeneration related to the context of the expanded polyglutamine tract in the disease protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1
Orr, H. T., Chung, M.-Y., Banfi, S., Kwiatkowski, T. J., Servadio, A., Beaudet, A. L., McCall, A. E., Duvick, L. A., Ranum, L. P. W., & Zoghbi, H. Y. (1993) · Nature Genetics · doi:10.1038/ng0793-221 · Cited by 1,632
Serine 776 of Ataxin-1 Is Critical for Polyglutamine-Induced Disease in SCA1 Transgenic Mice
Emamian, E. S., Kaytor, M. D., Duvick, L. A., Zu, T., Tousey, S. K., Zoghbi, H. Y., Clark, H. B., & Orr, H. T. (2003) · Neuron · doi:10.1016/s0896-6273(03)00258-7 · Cited by 305
Recovery from Polyglutamine-Induced Neurodegeneration in Conditional SCA1 Transgenic Mice
Zu, T., Duvick, L. A., Kaytor, M. D., Berlinger, M. S., Zoghbi, H. Y., Clark, H. B., & Orr, H. T. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2978-04.2004 · Cited by 262
A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor
Pollitt, S. K., Pallos, J., Shao, J., Desai, U. A., Ma, A. A. K., Thompson, L. M., Marsh, J. L., & Diamond, M. I. (2003) · Neuron · doi:10.1016/s0896-6273(03)00697-4 · Cited by 151
Cited by
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Neurofilaments: neurobiological foundations for biomarker applications
Gafson, A. R., Barthélemy, N. R., Bomont, P., Carare, R. O., Durham, H. D., Julien, J.-P., Kuhle, J., Leppert, D., Nixon, R. A., Weller, R. O., et al. (2020) · Brain · doi:10.1093/brain/awaa098 · Cited by 325
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“The ‘‘toxic oligomer’’ hypothesis is supported by the finding that a single-domain antibody can recognize a common conformational epitope that is displayed by several disease-associated proteins, including b-amyloid (Ab), a-synuclein (aSyn), tau protein, prions, and polyglutamine (polyQ) containing peptides (Hernandez…”
BackgroundSecondary Structure of Huntingtin Amino-Terminal Region
Kim, M. W., Chelliah, Y., Kim, S. W., Otwinowski, Z., & Bezprozvanny, I. (2009) · Structure · doi:10.1016/j.str.2009.08.002 · Cited by 255
Kinase inhibitors modulate huntingtin cell localization and toxicity
Atwal, R. S., Desmond, C. R., Caron, N., Maiuri, T., Xia, J., Sipione, S., & Truant, R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.582 · Cited by 204
“Data from CD spectroscopy and live-cell targeting assays suggest that conformational changes of huntingtin phospho-N17 (or N17 S13E S16E) may affect polyglutamine structure, perhaps leading to a conformer of huntingtin innocuous to the cel”
BackgroundSelf-citation
Metadata
- Authors
- Truant, R., Atwal, R. S., Desmond, C., Munsie, L., & Tran, T.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2008-08-07
- Volume
- 275
- Issue
- 17
- Pages
- 4252-4262
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W2111149100
- Cited by
- 111
- References
- 6
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Huntington’s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. https://app.cochat.ai/papers/10.1111/j.1742-4658.2008.06561.x
- The paper
- Truant, R., Atwal, R. S., Desmond, C., Munsie, L., & Tran, T. (2008). Huntington’s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. The FEBS Journal. https://doi.org/10.1111/j.1742-4658.2008.06561.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.